2020 International Meeting on the Molecular Biology of Hepatitis B Viruses

2020年乙型肝炎病毒分子生物学国际会议

基本信息

批准号：
9992951
负责人：
Ourania M. Andrisani
金额：
$ 0.9万
依托单位：
HEPATITIS B FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-09 至 2022-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9992951
关键词：
Achievement Address Anabolism Animal Model Animals Antiviral Agents Antiviral Therapy Asia Australia Award Basic Science Biochemistry Biology Biomedical Research Canada Cancer Etiology Cell model Cells Cellular biology Chronic Chronic Hepatitis B Communities Complement Country Data Development Disease Education Effectiveness Ensure Europe Financial Support Foundations Funding Gene Expression Genetic Transcription Goals Hepatitis B Hepatitis B Vaccines Hepatitis B Virus Hepatitis Delta Virus Hepatocyte Human Immunology International Light Link Liver Liver diseases Location Malignant neoplasm of liver Methods Mission Molecular Molecular Biology National Cancer Institute National Institute of Allergy and Infectious Disease National Institute of Diabetes and Digestive and Kidney Diseases National Institute of General Medical Sciences North America Oral Organoids Pathogenesis Postdoctoral Fellow Primary carcinoma of the liver cells Public Health RNA Editing Reagent Regulatory Element Reproducibility Research Research Personnel Resources Risk Scientist Senior Scientist Site Standardization Technology Time Training Travel Underrepresented Minority United States National Institutes of Health Universities Virus Virus Diseases Virus Shedding career cost drug development effective therapy gene therapy global health graduate student improved interest liver development meetings minority investigator mortality new technology novel strategies novel therapeutic intervention pathogen posters prevent programs prophylactic protein expression single cell sequencing social success therapy development tool vector virology virus development virus related cancer

项目摘要

ABSTRACT/SUMMARY Hepatitis B virus (HBV) infection is a significant global public health problem, with over 290 million people worldwide being chronically infected. Significantly, chronic HBV infection is associated with increased risk for development of hepatocellular carcinoma (HCC), the 2nd leading cause of cancer-related mortality worldwide. Despite the effectiveness of the prophylactic HBV vaccine, there is no cure for chronic HBV infection or the resultant liver cancer. There is compelling need to discover new therapeutic strategies to cure chronic HBV infection and HCC pathogenesis. Thus, the global HBV scientific community must continue to make directed strides towards understanding key, unanswered aspects of HBV biosynthesis and disease pathogenesis. The annual meeting on the Molecular Biology of Hepatitis B Viruses is the only forum that brings together the international community of scientists who study mechanisms of biosynthesis and pathogenesis by HBV and and its closely associated hepatitis delta virus (HDV). This International meeting on Hepatitis B Viruses has been held yearly since 1985, alternating at sites in North America, Europe, Asia and Australia. In 2020, the meeting will be held in Toronto, Canada. The success and achievements of the HBV field relies on the contributions of not only the established investigators but more importantly, on early career researchers (ECRs) that have/are deciding to enter the field, bringing with them new technology and concepts. Accordingly, the Specific Aim of this R13 application is: to promote and maximize attendance and participation of early career researchers/ECRs (graduate students & postdoctoral fellows) at the 2020 International HBV Meeting. The 2020 meeting will provide the stage for scientific exchange and dissemination of the latest research results that could influence new therapeutic strategies for HBV and HDV infections. It is estimated that 500-600 delegates will attend the 2020 meeting. The organization of the meeting will consist of 8 oral scientific sessions and 5 poster sessions including for the first time, e-poster presentations, as a training stage for early career scientists. In support of the goal of the global scientific strategy to cure HBV, keynote speakers will present new perspectives and technologies, and discuss standards that can be applied to advance the HBV field. To improve scientific interactions and scientific exchange, social gatherings are organized at the end of each meeting day. Significantly, since 2005, the International HBV meeting enjoys the continuing support from the Hepatitis B Foundation, minimizing the meeting costs, and publicizing the meeting to universities with large numbers of underrepresented minorities. To enable participation of early career trainees and underrepresented minority investigators, support from the National Institutes of Health to help defray the travel costs is requested. This funding will be used to ensure attendance and presentations by early career researchers, particularly from countries with lesser developed research capacity, as well as underrepresented minority investigators.

摘要/总结乙型肝炎病毒 (HBV) 感染是一个重大的全球公共卫生问题，有超过 2.9 亿人感染全世界都在慢性感染。值得注意的是，慢性乙型肝炎病毒感染与罹患以下疾病的风险增加相关：肝细胞癌 (HCC) 是全球癌症相关死亡的第二大原因。尽管预防性乙型肝炎疫苗有效，但无法治愈慢性乙型肝炎感染或慢性乙型肝炎。由此产生的肝癌。迫切需要发现治愈慢性乙型肝炎的新治疗策略感染和 HCC 发病机制。因此，全球乙型肝炎科学界必须继续做出有针对性的研究在理解乙型肝炎病毒生物合成和疾病发病机制的关键、尚未解答的方面取得了进展。乙型肝炎病毒分子生物学年会是唯一汇聚了众多专家的论坛研究 HBV 生物合成和发病机制的国际科学家团体及其密切相关的丁型肝炎病毒（HDV）。本次乙型肝炎病毒国际会议自 1985 年以来每年举办一次，轮流在北美、欧洲、亚洲和澳大利亚举办。 2020年，会议将在加拿大多伦多举行。 HBV领域的成功和成就依赖于以下人员的贡献不仅是已建立的研究人员，更重要的是，对于已经/正在从事的早期职业研究人员（ECR）决定进入该领域，带来新的技术和概念。因此，具体目标此 R13 应用程序是：促进并最大限度地提高早期职业研究人员/ECR 的出勤率和参与度（研究生和博士后）在2020年国际乙型肝炎会议上。 2020年会议将为科学交流和传播最新研究提供舞台结果可能会影响乙型肝炎病毒和丁型肝炎病毒感染的新治疗策略。估计500-600 代表将出席 2020 年会议。会议的组织将包括8场口头科学会议以及 5 场海报会议，其中包括首次的电子海报演示，作为早期职业生涯的培训阶段科学家。为了支持治愈乙型肝炎的全球科学战略的目标，主讲人将介绍新的观点和技术，并讨论可用于推进 HBV 领域发展的标准。改善每个会议日结束时都会组织科学互动和科学交流、社交聚会。值得注意的是，自2005年以来，国际乙型肝炎会议得到了乙型肝炎协会的持续支持基金会，最大限度地降低会议成本，并向拥有大量参会者的大学宣传会议代表性不足的少数群体。为了使早期职业受训者和代表性不足的少数族裔调查员能够参与，来自请求美国国立卫生研究院帮助支付旅费。这笔资金将用于确保早期职业研究人员，特别是来自欠发达国家的研究人员出席并发表演讲研究能力，以及少数族裔研究人员代表性不足的问题。